Nuvoton Releases High-Power Ultraviolet Laser Diode (379 nm, 1.0 W)
KYOTO, Japan, Jan. 20, 2026 /PRNewswire/ -- Nuvoton Technology Corporation Japan (hereinafter "NTCJ") announced on January 20 the start of mass production of its high-power ultraviolet semiconductor laser (379 nm, 1.0 W), which delivers...
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The...
Solace and NetComm Commercialize World's First Wirelessly Powered, Window-Mounted 5G CPE
MOUNT PEARL, NL and SYDNEY, Dec. 11, 2025 /PRNewswire/ -- Solace Power Inc. ("Solace") and NetComm Wireless ("NetComm") today announced a strategic partnership to co-develop and commercialize the world's first wirelessly powered, window-mounted...
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic...
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug...
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 21, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech...
A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO...
Canopus Networks & UNSW Sydney Secure $433K Grant from Australian Government to Commercialize AI-Powered Cloud Security
Australian Government backs Canopus Networks and UNSW on AI Cyber Defense for SMEs SYDNEY, March 24, 2025 /PRNewswire/ -- Canopus Networks and UNSW Sydney have secured a $433K grant from the Australian Government under the Australian Economic...